www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Teva_and_Kowa_Announce_Strategic_Partnership_to_Create_a_Leading_Generic_Pharmaceutical_Company_in_Japan_784019 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Kowa Company, Ltd. today announced that they ...http://www.finanzen.net/nachricht/Teva_and_Kowa_Announce_Strategic_Partnership_to_Create_a_Leading_Generic_Pharmaceutical_Company_in_Japan_784019http://www.finanzen.net/nachricht/Teva_s_ProAir_R_HFA_the_Market_Leading_Albuterol_Inhaler_Receives_New_Pediatric_Indication_783951 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir<sup id="bwanpa25"><span id="bwanpa3">®</sup> ...http://www.finanzen.net/nachricht/Teva_s_ProAir_R_HFA_the_Market_Leading_Albuterol_Inhaler_Receives_New_Pediatric_Indication_783951http://www.finanzen.net/nachricht/Teva_to_Present_at_the_UBS_Global_Life_Sciences_Conference_783836 <style type="text/css"> <!-- .bwcellpaddingleft0 {padding-left: 0.0px} .bwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .bwtablebottommargin {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} .bwtextalignleft {text-align: left} .bwverticalaligntop ...http://www.finanzen.net/nachricht/Teva_to_Present_at_the_UBS_Global_Life_Sciences_Conference_783836http://www.finanzen.net/nachricht/Teva_Introduces_Nicardipine_HCl_Injection_in_the_United_States_First_Alternative_to_Cardene_R_I_V__783292 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, which is ...http://www.finanzen.net/nachricht/Teva_Introduces_Nicardipine_HCl_Injection_in_the_United_States_First_Alternative_to_Cardene_R_I_V__783292http://www.finanzen.net/nachricht/Teva_Nord_Amerika_Chef_haelt_Stada_nicht_fuer_eine_gute_Akquisition_782623&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WASHINGTON (dpa-AFX) - Ein führender Manager des weltgrößten Generikaherstellers Teva Pharmaceutical Industries&nbsp;&nbsp;hat sich negativ zu einem Kauf des deutschen Generikaherstellers Stada Arzneimittel ...http://www.finanzen.net/nachricht/Teva_Nord_Amerika_Chef_haelt_Stada_nicht_fuer_eine_gute_Akquisition_782623http://www.finanzen.net/nachricht/COPAXONE_R_Demonstrated_Protective_Effect_in_Patients_with_Clinically_Isolated_Syndrome_Suggestive_of_Multiple_Sclerosis_782658 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} --> </style> New data from PreCISe, in clinically isolated syndrome patients, have demonstrated that COPAXONE<sup ...http://www.finanzen.net/nachricht/COPAXONE_R_Demonstrated_Protective_Effect_in_Patients_with_Clinically_Isolated_Syndrome_Suggestive_of_Multiple_Sclerosis_782658http://www.finanzen.net/nachricht/Laquinimod_Demonstrated_Significant_and_Sustained_Impact_on_Multiple_Sclerosis_Disease_Activity_782140 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> New data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis (RRMS) demonstrated a significant reduction ...http://www.finanzen.net/nachricht/Laquinimod_Demonstrated_Significant_and_Sustained_Impact_on_Multiple_Sclerosis_Disease_Activity_782140http://www.finanzen.net/nachricht/Longest_Prospective_Study_in_MS_Confirmed_Robust_Clinical_Benefits_and_Safety_of_COPAXONE_R__782139 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced new data from the longest prospective study of treatment to relapsing-remitting ...http://www.finanzen.net/nachricht/Longest_Prospective_Study_in_MS_Confirmed_Robust_Clinical_Benefits_and_Safety_of_COPAXONE_R__782139http://www.finanzen.net/nachricht/Expert_Says_Eshoo_Barton_Bill_Stifles_Drug_Innovation_781456 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} --> </style> Pending legislative proposals in Congress to create a follow-on biologics (FOBs) pathway risk overextending ...http://www.finanzen.net/nachricht/Expert_Says_Eshoo_Barton_Bill_Stifles_Drug_Innovation_781456http://www.finanzen.net/nachricht/Teva_Receives_EU_Marketing_Authorization_for_TevaGrastim_R__780762 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the European Commission<span id="bwanpa2">’s Directorate General for ...http://www.finanzen.net/nachricht/Teva_Receives_EU_Marketing_Authorization_for_TevaGrastim_R__780762